2696 Stoklara Genel Bakış Shanghai Henlius Biotech, Inc. onkoloji, otoimmün hastalıklar ve oftalmik hastalıklara odaklanarak biyolojik ilaçların araştırılması ve geliştirilmesi ile ilgilenmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Shanghai Henlius Biotech, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Shanghai Henlius Biotech Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$23.90 52 Haftanın En Yüksek Seviyesi HK$23.95 52 Haftanın En Düşük Seviyesi HK$11.60 Beta 0.83 1 Aylık Değişim 17.73% 3 Aylık Değişim 3.69% 1 Yıllık Değişim 104.27% 3 Yıllık Değişim -6.46% 5 Yıllık Değişim -40.25% Halka arzdan bu yana değişim -51.67%
Son Haberler & Güncellemeler
New major risk - Revenue and earnings growth Dec 13 Shanghai Henlius Biotech Announces Application for the Phase 1b/2 Clinical Trial of HLX43 for Injection Approved by the National Medical Products Administration
Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication of Hansizhuang (Serplulimab Injection) Dec 03
Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22 Nov 22
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) Oct 30
Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) Oct 24 Daha fazla güncelleme görün
New major risk - Revenue and earnings growth Dec 13 Shanghai Henlius Biotech Announces Application for the Phase 1b/2 Clinical Trial of HLX43 for Injection Approved by the National Medical Products Administration
Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication of Hansizhuang (Serplulimab Injection) Dec 03
Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22 Nov 22
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) Oct 30
Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) Oct 24
Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11 Oct 01
First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023) Sep 28
Shanghai Henlius Biotech, Inc. Receives Positive Opinion from the Committee Formedicinal Products for Human Use (Chmp)Of the European Medicines Agency (Ema) Sep 20
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of Pembrolizumab Biosimilar HLX17 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection) Sep 02
First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023) Aug 27
Shanghai Henlius Biotech, Inc. Announces Company Secretary Changes Aug 26
Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024 Aug 15
Shanghai Henlius Biotech, Inc. Announces the First Patient Dose in A Phase 2 Clinical Trial of HLX53 Aug 08
Shanghai Henlius Biotech, Inc. Announces International Multicentre Phase 3 Clinical Trial for the First-Line Treatment of Metastatic Colorectal Cancer in Japan Jul 03
Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes Jul 01
Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody Jun 28 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion. Jun 26
Investor sentiment improves as stock rises 19% Jun 26
Less than half of directors are independent Jun 25
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt? May 25 Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14
National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications May 23
Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration May 15
Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA) May 06
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China Apr 24
Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024 Apr 19
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration Apr 17
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints Apr 10
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints Apr 05
Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Mar 25
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 22
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection Mar 15 Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration
Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking Mar 10
Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration Feb 29
Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed Feb 01
Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load Dec 31
Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration Dec 27
New major risk - Financial position Dec 24
Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication Ofhansizhuang (Serplulimab Injection) in Combination Withchemotherapy for the First-Line Treatment Oflocally Advanced or Metastatic Non-Squamous Non-Smallcell Lung Cancer (NSCLC) Has Been Accepted By the National Medical Products Administration Dec 15
Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection) Dec 13
Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection Nov 29
Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection Nov 28
The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business Nov 25
Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor) Nov 24
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 Nov 21
New minor risk - Financial position Nov 17
Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023 Nov 04
Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Nov 01 Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND
Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial Oct 26
Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President Oct 05
Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody Sep 23
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt? Sep 18
Shanghai Henlius Biotech, Inc. Announces Executive Appointments Aug 29
First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022) Aug 26
Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023 Aug 16
Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet Aug 03
Forecast breakeven date moved forward to 2023 Jul 19 Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee
Consensus EPS estimates fall by 31% Jul 06
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023 Jul 06
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration Jun 27
Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26 Jun 16
Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry? May 31
Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26 May 06
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 26
Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues Apr 06
Consensus revenue estimates increase by 13% Apr 06
Forecast breakeven date moved forward to 2023 Apr 04
Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02 Feb 15
Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd) Feb 11
Shanghai Henlius Biotech, Inc. Announces the Phase 1b/2 Clinical Trial of Hlx07 Feb 03
Shanghai Henlius Biotech, Inc. Announces Dosage of First Subject in Phase 1 Clinical Study of HLX15 (Recombinant Anti-CD38 Humanmonoclonal Antibody Injection) in Healthy Chinese Male Subjects Feb 02 Shanghai Henlius Biotech, Inc. Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC
Shanghai Henlius Biotech Announces the First Patient Dosage in the United States of America in an International Multi-Centre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) Jan 06
Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in A Phase 1 Clinical Trialof Hlx60 (Recombinant Humanized Anti-Garp Monoclonalantibody Injection) in Combination with Hansizhuang(Serplulimab Injection) for the Treatment of Advanced Ormetastatic Solid Tumors in Australia Dec 16
Shanghai Henlius Biotech, Inc. Doses First Patient in A Phase 1 Clinical Trial of anti-TIGIT Fc Fusion Protein HLX53 for the Treatment of advanced/Metastatic Solid Tumours or Lymphomasin Mainland China Dec 10
Shanghai Henlius Biotech, Inc. Announces the First Patient Was Dosed in NCT05468489 Dec 01
Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Bridging Study Comparing Hansizhuang (Serplulimab Injection) Versus Atezolizumab Nov 30
Shanghai Henlius Biotech, Inc. Announces Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy Approved to Commence A Phase 3 Clinical Trial Nov 19
Less than half of directors are independent Nov 16
Shanghai Henlius Biotech, Inc. Announces Application for Phase 1b/2 Clinical Trial of HLX208 Nov 12
Shanghai Henlius Biotech, Inc. Receives Investigational New Drug Approval from China's National Medical Products Administration for A Phase 2 Clinical Trial of AC101 Nov 10
Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication Ofhansizhuang (Serplulimab Injection) in Combination Withchemotherapy for the First-Line Treatment of Squamousnon-Small Cell Lung Cancer Has Been Approved by Thenational Medical Products Administration Nov 02 Shanghai Henlius Biotech, Inc. announces the Phase 2 Clinical Trial of Hlx22 in Combination Withhansizhuang (Serplulimab Injection) and Thestandard Therapy As the First-Line Treatment for Locally Advancedor Metastatic Gastric Cancer (Gc) Has Been Approvedby the National Medical Products Admin
Shanghai Henlius Biotech, Inc. Announces Approval of Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy to Commence A Phase 3 Clinical Trial for the Treatment of Limited-Stage Small Cell Lung Cancer in Australia Oct 26 Hissedar Getirileri 2696 HK Biotechs HK Pazar 7D 7.7% -3.9% -0.5% 1Y 104.3% -5.7% 19.9%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 2696 geçen yıl % -5.7 oranında getiri sağlayan Hong Kong Biotechs sektörünü aştı.
Getiri vs Piyasa: 2696 geçen yıl % 19.9 oranında getiri sağlayan Hong Kong Piyasasını aştı.
Fiyat Oynaklığı Is 2696's price volatile compared to industry and market? 2696 volatility 2696 Average Weekly Movement 3.2% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
İstikrarlı Hisse Senedi Fiyatı: 2696 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 2696 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Shanghai Henlius Biotech, Inc. onkoloji, otoimmün hastalıklar ve oftalmik hastalıklara odaklanarak biyolojik ilaçların araştırma ve geliştirme faaliyetlerini yürütmektedir. Hodgkin olmayan lenfoma, kronik lenfositik lösemi ve romatoid artrit tedavisi için bir rituksimab enjeksiyonu olan HANLIKANG; meme ve metastatik meme ve mide kanserini tedavi etmek için bir trastuzumab enjeksiyonu olan HANQUYOU sunmaktadır; HANDAYUAN, romatoid artrit, ankilozan spondilit, plak sedef hastalığı ve üveit tedavisi için bir adalimumab enjeksiyonu; HANBEITAI, metastatik kolorektal kanser (mCRC) ve tekrarlayan küçük hücreli dışı akciğer kanserini tedavi etmek için bir bevacizumab enjeksiyonu; ve HANSIZHUANG, mikrosatellit instabilitesi yüksek solid tümörler için bir serplulimab enjeksiyonu. Şirket ayrıca skuamöz hücreli karsinomlar, mide kanseri, küçük hücreli akciğer kanseri, hepatosellüler karsinom, metastatik kolorektal kanser, solid tümörler, SCCHN, sqNSCLC, hepatosellüler karsinom ve özofageal skuamöz hücreli karsinomu tedavi etmek için Serplulimab; yaşlılığa bağlı maküler dejenerasyon için bir anti-VEGF monoklonal antikor enjeksiyonu olan HLX04-O geliştirmektedir; Meme ve metastatik mide kanserini tedavi etmek için HLX22; idiyopatik pulmoner fibrozu tedavi etmek için HLX6018; solid tümörleri tedavi etmek için HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53 ve HLX51; meme kanserini tedavi etmek için HLX11; mCRC ve SCCHN için bir cetuximab enjeksiyonu olan HLX05; ve osteoporozu tedavi etmek için HLX14.
Daha fazla göster Shanghai Henlius Biotech, Inc. Temel Bilgiler Özeti Shanghai Henlius Biotech'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 2696 temel i̇stati̇sti̇kler Piyasa değeri HK$12.99b Kazançlar(TTM ) HK$737.84m Gelir(TTM ) HK$6.01b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 2696 gelir tablosu (TTM ) Gelir CN¥5.64b Gelir Maliyeti CN¥1.51b Brüt Kâr CN¥4.13b Diğer Giderler CN¥3.44b Kazançlar CN¥692.34m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/21 05:20 Gün Sonu Hisse Fiyatı 2024/12/20 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Shanghai Henlius Biotech, Inc. 15 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Yang Huang BofA Global Research Wangbin Zhou Citigroup Inc Eva Zhao Citigroup Inc
Göster 12 daha fazla analist 
